Vernon K. Sondak, MD

Dr. Park addresses management of low-grade immune-related adverse events (irAEs), the most common toxicities encountered with checkpoint inhibitors, including dermatitis, pruritus, and GI symptoms.

Dr. Zager outlines a monitoring strategy for the Case 1 patient who is NED following surgery and radiation.

Expert panel explains extremely high-risk cutaneous SCC after surgery and radiation, and why adjuvant cemiplimab may curb recurrence.

Real-world cemiplimab data and neoadjuvant results show strong responses in high-risk cutaneous SCC, guiding treatment for frail, complex patients.

C-POST shows adjuvant cemiplimab cuts recurrence risk in high‑risk cutaneous SCC after surgery and radiation, reshaping multidisciplinary care.

Learn red flags for advanced cutaneous SCC and how PD‑1/PD‑L1 immunotherapy offers durable responses, reshaping treatment beyond surgery.

Learn when high-risk skin SCC needs early oncology referrals, imaging, and coordinated tumor-board care to avoid delays and improve outcomes.

Learn how clinicians spot aggressive cutaneous squamous cell carcinoma and when multidisciplinary care and immunotherapy improve outcomes.

CLND as standard of care for patients with SLN-positive metastatic melanoma is supported by a wealth of compelling prospective data.

Haigh et al provide thoughtful, detailed summary of 3 decades of intensive work aimed at developing active, specific immuno-therapies (vaccines) for patients with melanoma. However, as the 20th century draws to a close, the key question is: Can any vaccine be considered an effective therapy for patients with melanoma? To rephrase the question: What constitutes proof of efficacy for a melanoma vaccine, and have any vaccines met those criteria? In a word, the answer to the first question is “no.” The answer to the second question, however, requires more elaboration.